Roelof A J Smit1, Stella Trompet1, Behnam Sabayan1, Saskia le Cessie1, Jeroen van der Grond1, Mark A van Buchem1, Anton J M de Craen1, J Wouter Jukema1. 1. From Department of Cardiology (R.A.J.S., S.T., J.W.J.), Section of Gerontology and Geriatrics, Department of Internal Medicine (R.A.J.S., S.T., B.S., A.J.M.d.C.), Department of Radiology (B.S., J.v.d.G., M.A.v.B.), Department of Clinical Epidemiology (S.l.C.), Department of Medical Statistics and Bioinformatics (S.l.C.), and Einthoven Laboratory for Experimental Vascular Medicine (J.W.J.), Leiden University Medical Center, Leiden, The Netherlands; and Interuniversity Cardiology Institute Netherlands, Utrecht, The Netherlands (J.W.J.).
Abstract
BACKGROUND: Recently, it was shown that intraindividual variation in low-density lipoprotein cholesterol (LDL-C) predicts both cerebrovascular and cardiovascular events. We aimed to examine whether this extends to cognitive function and examined possible pathways using a magnetic resonance imaging substudy. METHODS: We investigated the association between LDL-C variability and 4 cognitive domains at month 30 in 4428 participants of PROSPER (PROspective Study of Pravastatin in the Elderly at Risk). Additionally, we assessed the association of LDL-C variability with neuroimaging outcomes in a subset of 535 participants. LDL-C variability was defined as the intraindividual standard deviation over 4 postbaseline LDL-C measurements, and all analyses were adjusted for mean LDL-C levels and cardiovascular risk factors. RESULTS: Higher LDL-C variability was associated with lower cognitive function in both the placebo and pravastatin treatment arms. Associations were present for selective attention (P=0.017 and P=0.11, respectively), processing speed (P=0.20 and P=0.029), and memory (immediate recall, P=0.002 and P=0.006; delayed recall, P=0.001 and P≤0.001). Furthermore, higher LDL-C variability was associated with lower cerebral blood flow in both trial arms (P=0.031 and P=0.050) and with greater white matter hyperintensity load in the pravastatin arm (P=0.046). No evidence was found for interaction between LDL-C variability and pravastatin treatment for both cognitive and magnetic resonance imaging outcomes. CONCLUSIONS: We found that higher visit-to-visit variability in LDL-C, independently of mean LDL-C levels and statin treatment, is associated with lower cognitive performance, lower cerebral blood flow, and greater white matter hyperintensity load.
RCT Entities:
BACKGROUND: Recently, it was shown that intraindividual variation in low-density lipoprotein cholesterol (LDL-C) predicts both cerebrovascular and cardiovascular events. We aimed to examine whether this extends to cognitive function and examined possible pathways using a magnetic resonance imaging substudy. METHODS: We investigated the association between LDL-C variability and 4 cognitive domains at month 30 in 4428 participants of PROSPER (PROspective Study of Pravastatin in the Elderly at Risk). Additionally, we assessed the association of LDL-C variability with neuroimaging outcomes in a subset of 535 participants. LDL-C variability was defined as the intraindividual standard deviation over 4 postbaseline LDL-C measurements, and all analyses were adjusted for mean LDL-C levels and cardiovascular risk factors. RESULTS: Higher LDL-C variability was associated with lower cognitive function in both the placebo and pravastatin treatment arms. Associations were present for selective attention (P=0.017 and P=0.11, respectively), processing speed (P=0.20 and P=0.029), and memory (immediate recall, P=0.002 and P=0.006; delayed recall, P=0.001 and P≤0.001). Furthermore, higher LDL-C variability was associated with lower cerebral blood flow in both trial arms (P=0.031 and P=0.050) and with greater white matter hyperintensity load in the pravastatin arm (P=0.046). No evidence was found for interaction between LDL-C variability and pravastatin treatment for both cognitive and magnetic resonance imaging outcomes. CONCLUSIONS: We found that higher visit-to-visit variability in LDL-C, independently of mean LDL-C levels and statin treatment, is associated with lower cognitive performance, lower cerebral blood flow, and greater white matter hyperintensity load.
Authors: Rizwan Kalani; Traci M Bartz; Astrid Suchy-Dicey; Mitchell S V Elkind; Bruce M Psaty; Lester Y Leung; Kenneth Rice; David Tirschwell; W T Longstreth Journal: Stroke Date: 2019-12-17 Impact factor: 7.914
Authors: Beth A Taylor; Alecia D Dager; Gregory A Panza; Amanda L Zaleski; Shashwath Meda; Gregory Book; Michael C Stevens; Sarah Tartar; C Michael White; Donna M Polk; Godfrey D Pearlson; Paul D Thompson Journal: Am Heart J Date: 2017-12-06 Impact factor: 4.749
Authors: Melissa Lamar; Ramon A Durazo-Arvizu; Carlos J Rodriguez; Robert C Kaplan; Marisa J Perera; Jianwen Cai; Rebeca A Espinoza Giacinto; Hector M González; Martha L Daviglus Journal: J Int Neuropsychol Soc Date: 2019-09-23 Impact factor: 2.892
Authors: Ane Iriondo; Maite García-Sebastian; Arantzazu Arrospide; Maria Arriba; Sara Aurtenetxe; Myriam Barandiaran; Montserrat Clerigue; Mirian Ecay-Torres; Ainara Estanga; Alazne Gabilondo; Andrea Izagirre; Jon Saldias; Mikel Tainta; Jorge Villanua; Javier Mar; Felix M Goñi; Pablo Martínez-Lage Journal: Brain Imaging Behav Date: 2021-04 Impact factor: 3.978